Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.
Actively Recruiting
Researchers are evaluating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer mCSPC who have not received androgen receptor pathway inhibitors or chemotherapy for mCSPC. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study focuses on participants with prior limited androgen-deprivation therapy and no disease progression or rising PSA before treatment starts. Participants are randomly assigned to one of two groups one receives mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, and the other receives a placebo plus enzalutamide at the same dose. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up. Treatment is oral and taken continuously during the trial. During the study, participants undergo various assessments including imaging scans to track disease progression, laboratory tests, and patient-reported questionnaires on pain, quality of life, and fatigue. Researchers will monitor radiographic progression-free survival for up to about 4 years and overall survival for up to about 9 years. Safety and pharmacokinetics of mevrometostat combined with enzalutamide are also evaluated. The total duration includes screening, treatment, safety monitoring, and extended follow-up phases.